This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Logo

Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry

Sponsored by Midwest Biomedical Research Foundation

About this trial

Last updated 3 years ago

Study ID

PS0035

Status

Recruiting

Type

Observational

Placebo

No

Accepting

18+ Years
All Sexes

Trial Timing

Started 20 years ago

What is this trial about?

The purpose of this study is to determine or evaluate the risk factors such as smoking, family history etc. that cause esophageal cancer and to determine the genetic changes that lead to esophageal cancer. The investigators hypothesis is that systematic collection of data on the natural history of GERD and BE patients and risk factors for development of BE in patients with chronic GERD and progression of BE to dysplasia and adenocarcinoma will provide useful information to develop a decision model for risk stratification and risk reduction strategies in these patients. As of March 17, 2011, 585 patients have consented at the Kansas City VA Medical Center.

What are the participation requirements?

Inclusion Criteria

All patients must be eligible for care that the Kansas City VA Hospital where this study was approved for enrollment. * Kansas City VA Patients with confirmed BE with and without dysplasia and patients with reflux disease (patients/cases); patients with other indicators for endoscopy such as anemia, weight loss, diarrhea, but without GERD and PE (controls).

Exclusion Criteria

* Patients with uncontrolled significant comorbidities such as cardiovascular, pulmonary, renal, hepatic or metabolic diseases. * Presence of anticoagulation that would increase risk from biopsies * Patients unable to provide history * Patients with dyspepsia